Valuation: Edesa Biotech, Inc.

Market Cap 52.31M 45.34M 42.5M 38.76M 72.92M 4.99B 74.09M 500M 195M 2.5B 196M 192M 8.34B P/E 2026 *
-3.27x
P/E 2027 * -2.7x
Enterprise Value 52.31M 45.34M 42.5M 38.76M 72.92M 4.99B 74.09M 500M 195M 2.5B 196M 192M 8.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.25%
Yield 2026 *
-
Yield 2027 * -
1 day+2.45%
1 week+5.03%
Current month+6.26%
1 month-22.54%
3 months-59.08%
6 months+445.73%
Current year+282.39%
1 week 5.1
Extreme 5.1
5.78
1 month 4.5
Extreme 4.5
7.16
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Free

Founder

5,324 0.0553%
7/2/26 Free

Founder

3,378 0.0380%
3/4/26 Buy

Founder

1,000 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%+5.03%+150.23%-12.84% 51.06M
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.87%+0.77%+36.57%+65.91% 54.93B
-4.50%+27.58%+3.55%+463.22% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
-0.67%-0.07%-17.01%-13.84% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.03%+46.32%-20.56% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.46%-10.74%+33.36%+135.18% 12.48B
Average -0.18%+7.62%+66.82%+177.63% 26.69B
Weighted average by Cap. -0.21%+8.03%+55.76%+163.02%

Financials

2026 *2027 *
Net sales - -
Net income -14.54M -12.6M -11.81M -10.77M -20.26M -1.39B -20.59M -139M -54.3M -694M -54.57M -53.39M -2.32B -26.51M -22.98M -21.54M -19.64M -36.96M -2.53B -37.55M -254M -99.03M -1.27B -99.54M -97.38M -4.23B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
26-08-13 US$5.430 +2.45% 34,879
26-08-12 US$5.300 -3.99% 26,305
26-08-11 US$5.520 +5.34% 34,111
26-08-10 US$5.240 -0.57% 37,072
26-08-07 US$5.270 +4.36% 54,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.430USD
Average target price
16.33USD
Spread / Average Target
+200.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock